Placebo News and Research

RSS

First patients dosed in Neurotrope's Bryostatin-1 Phase 2b trial for treatment of advanced Alzheimer’s disease

Neurotrope, Inc. today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s disease.

16 Feb 2016

Modulation of opioid system may improve effectiveness of drugs for treatment-resistant depression

A clinical trial of an experimental drug for treatment-resistant major depression finds that modulation of the endogenous opioid system may improve the effectiveness of drugs that target the action of serotonin and related monoamine neurotransmitters.

12 Feb 2016

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015.

12 Feb 2016

Scientists find that daily dose of beetroot juice significantly improves exercise endurance, blood pressure

Scientists at Wake Forest Baptist Medical Center have found that a daily dose of beetroot juice significantly improved exercise endurance and blood pressure in elderly patients with heart failure with preserved ejection fraction (HFPEF).

11 Feb 2016

Oral therapeutic drug shows promise against recurrent C. difficile infection

Results from a Phase 1b/2 trial suggest that an investigational microbiome-based, oral therapeutic drug is effective for the treatment of recurrent C. difficile infection. In a paper published online in the Journal of Infectious Diseases, a multi-institutional research team reports that treatment with the preparation, containing the spores of approximately 50 species of beneficial bacteria, successfully prevented recurrence of C. difficile infection (CDI) in patients with a history of multiple recurrent disease.

10 Feb 2016

Medical marijuana offers hope for kids with uncontrolled seizures

Desperate for relief, parents are taking unusual steps to help children plagued with seizures. The relief, however, comes in a most unlikely form: marijuana.

9 Feb 2016

FDA's PDAC supports use of Brintellix for treating cognitive dysfunction in adults with MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted 8 to 2 that the companies presented substantial evidence to support the effectiveness of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD).

5 Feb 2016

Novel non-invasive method of vagus nerve stimulation reduces depressive symptoms

Researchers of a new study published in the current issue of Biological Psychiatry report successful reduction of depressive symptoms in patients using a novel non-invasive method of vagus nerve stimulation, or VNS.

5 Feb 2016

Using corticosteroids before late preterm delivery reduces respiratory complications in babies

A multicenter clinical trial led by researchers at Columbia University Medical Center and NewYork-Presbyterian has found that the use of corticosteroids in mothers at risk for late preterm delivery significantly reduced the incidence of severe respiratory complications in their babies.

5 Feb 2016

Noninvasive FMRI may help evaluate effectiveness of new pain medications

New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.

4 Feb 2016

NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

The National Institute for Health and Care Excellence has issued its final guidance recommending Xofigo for use on the NHS in England and Wales as an option for treating adult men, with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy.

4 Feb 2016

UCI researchers identify potential strategies to prevent cognitive decline

As brain cells age they lose the fibers that receive neural impulses, a change that may underlie cognitive decline. Researchers at the University of California, Irvine recently found a way to reverse this process in rats. The study was published February 3 in The Journal of Neuroscience. Researchers caution that more studies are needed, but the findings shed light on the mechanisms of cognitive decline and identify potential strategies to stem it.

3 Feb 2016

Use of antenatal steroids during late preterm delivery prevents neonatal respiratory complications

In a study to be presented on Feb. 4 in the oral plenary session at 8 a.m. EST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Atlanta, researchers with the Eunice Kennedy Shriver National Institute of Child Health and Human Development and Maternal-Fetal Medicine Units Network found that the administration of antenatal steroids in pregnancies at risk for late preterm delivery prevents respiratory and other neonatal complications.

2 Feb 2016

Unobtrusive patch on the forehead provides relief from PTSD

An average of 30 years had passed since the traumatic events that had left them depressed, anxious, irritable, hypervigilant, unable to sleep well and prone to nightmares.

30 Jan 2016

Fingolimod trial INFORMS primary progressive MS strategy

Fingolimod is unable to slow disability progression or brain volume loss in patients with primary progressive multiple sclerosis, show the findings of the INFORMS study.

29 Jan 2016

Neuroprotection powers for phenytoin in acute optic neuritis

Selective sodium channel blockade with the anti-epileptic drug phenytoin protects against acute demyelinating optic neuritis, researchers report.

29 Jan 2016

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S.

29 Jan 2016

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

AbbVie, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo.

29 Jan 2016

Dysport phase III study results in children with cerebral palsy with lower limb spasticity published in Pediatrics

Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.

28 Jan 2016

NTCELL stops Parkinson’s disease progression one year after treatment

Over a year after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease remain well, and at 58 weeks post-implant there are no safety concerns.

28 Jan 2016

Placebo News and Research

First patients dosed in Neurotrope's Bryostatin-1 Phase 2b trial for treatment of advanced Alzheimer’s disease

Modulation of opioid system may improve effectiveness of drugs for treatment-resistant depression

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Scientists find that daily dose of beetroot juice significantly improves exercise endurance, blood pressure

Oral therapeutic drug shows promise against recurrent C. difficile infection

Medical marijuana offers hope for kids with uncontrolled seizures

FDA's PDAC supports use of Brintellix for treating cognitive dysfunction in adults with MDD

Novel non-invasive method of vagus nerve stimulation reduces depressive symptoms

Using corticosteroids before late preterm delivery reduces respiratory complications in babies

Noninvasive FMRI may help evaluate effectiveness of new pain medications

NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

UCI researchers identify potential strategies to prevent cognitive decline

Use of antenatal steroids during late preterm delivery prevents neonatal respiratory complications

Unobtrusive patch on the forehead provides relief from PTSD

Fingolimod trial INFORMS primary progressive MS strategy

Neuroprotection powers for phenytoin in acute optic neuritis

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

Dysport phase III study results in children with cerebral palsy with lower limb spasticity published in Pediatrics

NTCELL stops Parkinson’s disease progression one year after treatment

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News